Increases in miRs-29a and miRs-29a-660 which target TET2 and EPAS1 decrease miR-494 thereby increasing CML LSC TKI-resistance [91]. This evidence concerns the gene EPAS1 and chronic myelogenous leukemia, BCR-ABL1 positive.